Dermatology
Podcast | Common Skin Complaints in Primary Care.
21 Jul, 2021 | 10:22h | UTC#285 Common Skin Complaints in Primary Care – The Curbsiders
2021 ACR Guideline for the Management of Polyarteritis Nodosa.
13 Jul, 2021 | 09:37h | UTC
Viewpoint | Active surveillance as a management option for low-risk basal cell carcinoma.
15 Jun, 2021 | 08:49h | UTC
COVID nails: these changes to your fingernails may show you’ve had coronavirus.
10 Jun, 2021 | 09:42h | UTCCOVID nails: these changes to your fingernails may show you’ve had coronavirus – The Conversation
COVID-19 Imaging: What we know now and what remains unknown.
9 Jun, 2021 | 08:27h | UTCCOVID-19 Imaging: What We Know Now and What Remains Unknown – Radiology
Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection – there was a significant association between skin rashes and a positive swab test result (odds ratio 1.67).
8 Jun, 2021 | 09:26h | UTCDiagnostic value of cutaneous manifestation of SARS-CoV-2 infection – British Journal of Dermatology
Practice Pointer | Mask related acne (“maskne”) and other facial dermatoses.
8 Jun, 2021 | 09:24h | UTCMask related acne (“maskne”) and other facial dermatoses – The BMJ
Commentary on Twitter
The term “maskne” has become increasingly popular during the pandemic, particularly in the media.
This #BMJInfographic presents common distributions that can be used as a starting point for assessment @will_s_t https://t.co/mKQUaN3PYY pic.twitter.com/OCBuFxiY9s
— The BMJ (@bmj_latest) June 7, 2021
RCT: Among patients with pemphigus vulgaris, rituximab was superior to mycophenolate mofetil in producing sustained complete remission at 52 weeks (40% vs 10%) but was associated with increased risk of serious adverse events (22% vs. 15%).
24 May, 2021 | 08:24h | UTC
New Google AI tool can help patients identify common skin conditions.
24 May, 2021 | 08:23h | UTCUsing AI to help find answers to common skin conditions – Google
Commentary: Google AI tool can help patients identify skin conditions – BBC
Review: Histiocytosis
4 May, 2021 | 08:29h | UTC
New studies in patients with moderate-to-severe psoriasis show greater skin clearance with Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F
25 Apr, 2021 | 21:08h | UTCStudy 1: Bimekizumab versus Secukinumab in Plaque Psoriasis – New England Journal of Medicine
Study 2: Bimekizumab versus Adalimumab in Plaque Psoriasis – New England Journal of Medicine
Related studies: Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase trial – The Lancet AND Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial – The Lancet
RCT: Atenolol has similar efficacy as propranolol with fewer adverse events in the treatment of problematic infantile hemangiomas
20 Apr, 2021 | 05:32h | UTCEfficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – $ for full-text)
Diagnosis and management of leukocytoclastic vasculitis
14 Apr, 2021 | 01:26h | UTCDiagnosis and management of leukocytoclastic vasculitis – Internal and Emergency Medicine
Cohort study: Higher cumulative exposure to Thiazide diuretics linked to an increased risk of skin cancer in people older than 65 years
13 Apr, 2021 | 05:08h | UTCCommentaries: Thiazides May Up Risk for Skin Cancer in Older Adults – HealthDay AND Some blood pressure medication linked to higher risk of skin cancer, study finds – CTV News
Related study: Case-Control Study: Possible Association of Hydrochlorothiazide Use and Risk of Melanoma
Guidelines of care for the management of actinic keratosis
9 Apr, 2021 | 03:20h | UTC
RCT: Upadacitinib vs. Adalimumab for Psoriatic Arthritis
5 Apr, 2021 | 00:57h | UTCTrial of Upadacitinib and Adalimumab for Psoriatic Arthritis – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: Abrocitinib vs. Placebo or Dupilumab for Atopic Dermatitis
26 Mar, 2021 | 08:27h | UTCAbrocitinib versus Placebo or Dupilumab for Atopic Dermatitis – New England Journal of Medicine
Systematic review: Interventions for cutaneous disease in systemic lupus erythematosus
17 Mar, 2021 | 02:30h | UTCInterventions for cutaneous disease in systemic lupus erythematosus – Cochrane Library
Clinical Update: Diagnosis and Treatment of Nonscarring Hair Loss in Primary Care in 2021
10 Mar, 2021 | 08:14h | UTCDiagnosis and Treatment of Nonscarring Hair Loss in Primary Care in 2021 – JAMA (free for a limited period)
Some experience delayed rash after Moderna shot, study says
5 Mar, 2021 | 08:44h | UTCSome Experience Delayed Rash After Moderna Shot, Study Says – Bloomberg
Original study: Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 – New England Journal of Medicine
Expert consensus on practical aspects in the treatment of chronic urticaria
3 Mar, 2021 | 08:28h | UTC
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis
2 Mar, 2021 | 01:24h | UTCPhase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
The tubulin polymerization and Src kinase inhibitor tirbanibulin was superior to placebo ointment in clearing actinic keratoses on the face and scalp at 2 months. As is typical of the disorder, lesions recurred in 47% of patients at 1 year.
— NEJM (@NEJM) February 17, 2021
Indian Guidelines for pediatric skin care in neonates, infants, and children
28 Feb, 2021 | 20:37h | UTCIndian Academy of Pediatrics Guidelines for Pediatric Skin Care
Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)
23 Feb, 2021 | 01:57h | UTC
Cohort study: Association of potent and very potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures
26 Jan, 2021 | 00:38h | UTCEditorial: Topical Corticosteroids and Glucocorticoid-Induced Osteoporosis—Cumulative Dose and Duration Matter
Commentaries: Prolonged Use of Topical Steroids Associated with Increased Risk of Osteoporosis – Physician’s Weekly AND Potent Topical Corticosteroids Tied to Increased Fracture Risk – NEJM Journal Watch
Author Interview: Association of Topical Corticosteroids and Risk of Osteoporosis and Major Osteoporotic Fractures – JAMA
Commentary on Twitter
In a cohort study of 723 251 users of potent or very potent topical #corticosteroids, use of these drugs was associated with increased risk of #osteoporosis and major osteoporotic fracture with a dose-response association for cumulative use https://t.co/m5Rp4n0NvK
— JAMA Dermatology (@JAMADerm) January 20, 2021